Biogen’s higher Spinraza dose shows better efficacy in Phase II/III trial
Biogen plans to apply for regulatory approval of this investigational dose regimen following positive trial data.
![](https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/09/shutterstock_2364219167-e1725635287397.jpg)
Biogen plans to apply for regulatory approval of this investigational dose regimen following positive trial data.
Representatives of the WHO and the IFRC called for international cooperation to tackle the current mpox outbreak.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Combating Pharmaceutical Crime with On-Dose Authentication
Syntekabio and Enamine partner for AI-based drug development
Novavax wins FDA emergency approval for updated Covid-19 vaccine
How AI can help tackle the challenges of precision and personalised medicine